Chargement en cours...
Molecular signatures of chronic myeloid leukemia stem cells
BCR-ABL tyrosine kinase inhibitors (TKIs) are effective in controlling Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML) are unlikely to cure the disease because TKIs are unable to eradicate leukemia stem cells (LSCs) responsible for the disease relapse even after tyrosine kinase inhibiti...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4177606/ https://ncbi.nlm.nih.gov/pubmed/24252550 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2050-7771-1-21 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|